Capitalization 1,650B 1.19B 92.93B P/E ratio 2024 *
-
P/E ratio 2025 * -
Enterprise value 807M 584K 45.48M EV / Sales 2024 *
37x
EV / Sales 2025 * 18.6x
Free-Float
86.61%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease CI
Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease CI
Oscotec Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib CI
Oscotec Inc. announced that it has received KRW 29.9999073 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd., Meritz Securities Co., Ltd., Investment Arm, Asset One Asset Management CI
Oscotec Inc. announced that it expects to receive KRW 29.9999073 billion in funding from Tiger Asset Management Discretionary Investment Co., Ltd., Meritz Securities Co., Ltd., Investment Arm, Asset One Asset Management CI
Oscotec Inc. and Beactica Therapeutics AB Announces License and Collaboration Agreement to Develop New Cancer Drug CI
Oscotec Inc. announced that it has received KRW 21.9999934 billion in funding from E&Investment,Inc. CI
Oscotec Inc. announced that it expects to receive KRW 21.9999934 billion in funding from E&Investment,Inc. CI
Oscotec Inc. announced that it has received KRW 19.9999584 billion in funding from E&INVESTMENT INC., Samsung Securities Co. Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, AJU IB INVESTMENT Co., Ltd. CI
Oscotec Inc. announced that it expects to receive KRW 19.9999584 billion in funding from E&INVESTMENT INC., Samsung Securities Co. Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, AJU IB INVESTMENT Co., Ltd. CI
Oscotec Inc. announced that it has received KRW 10 billion in funding from a group of investors CI
Oscotec Inc. announced that it expects to receive KRW 10 billion in funding from a group of investors CI
More news
1 day+2.73%
1 week+1.41%
Current month+15.05%
1 month+21.86%
3 months+39.13%
6 months+116.54%
Current year+87.42%
More quotes
1 week
41 050.00
Extreme 41050
43 300.00
1 month
34 100.00
Extreme 34100
44 900.00
Current year
18 540.00
Extreme 18540
44 900.00
1 year
18 000.00
Extreme 18000
44 900.00
3 years
15 850.00
Extreme 15850
44 900.00
5 years
14 900.00
Extreme 14900
71 500.00
10 years
1 450.00
Extreme 1450
71 500.00
More quotes
Insider TitleAgeSince
Chief Executive Officer 61 -
Chief Executive Officer 64 07/12/98
Chief Tech/Sci/R&D Officer 61 -
Insider TitleAgeSince
Chief Executive Officer 64 07/12/98
Director/Board Member 51 31/08/99
Chief Executive Officer 61 -
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+2.73%+1.41%+54.84%+24.86% 1.2B
-0.52%+0.92%-1.94%-10.42% 73.15B
-1.05%-1.55%+15.05%-16.57% 10.84B
+1.03%+1.24%+55.83%+83.79% 5.3B
+1.43%-0.12%+0.47%-30.33% 4.83B
-5.86%-14.28%+30.95%+128.24% 2.99B
-1.16%-3.16%+10.02%+24.69% 2.21B
+2.34%-0.19%-39.29%-67.17% 1.82B
+0.11%+6.05%+1.92%+12.67% 1.67B
-.--%-.--% - - 1.64B
Average -0.09%-1.45%+14.20%+16.64% 10.56B
Weighted average by Cap. -0.49%-0.33%+4.15%-2.66%
See all sector performances

Financials

2024 *2025 *
Net sales 42.5B 30.77M 2.39B 83B 60.09M 4.68B
Net income - -
Net Debt -79B -57.2M -4.45B -106B -77.11M -6B
More financial data * Estimated data
Logo Oscotec Inc.
Oscotec Inc.,Ltd is a Korea-based company mainly engaged in the manufacture of functional medical materials and related products. The Company operates its business through three divisions: new medicines division, functional material products division and dental bone graft division. Its new medicines division provides osteoporosis drugs, arthritis drugs and periodontal disease drugs. Its functional material products division provides functional materials and food used for promoting bone growth and periodontal health. Its dental bone graft division provides bone graft materials, membranes and centrifuges. The Company distributes its products within domestic market and to overseas markets.
Employees
54
More about the company
Date Price Change Volume
24/07/24 43,200.00 +2.73% 217,180
23/07/24 42,050.00 -0.71% 241,685
22/07/24 42,350.00 +0.83% 315,159
19/07/24 42,000.00 -2.55% 255,452
18/07/24 43,100.00 +1.17% 499,584

End-of-day quote Korea S.E., July 23, 2024

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
43,200.00KRW
Average target price
56,000.00KRW
Spread / Average Target
+29.63%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A039200 Stock